Novel method of myocardial imaging
AssigneeMedco Research, Inc.
InventorsSyed M. Mohiuddin, Daniel E. Hilleman
Life of this patent
Estimating the term…
Abstract
The parenteral use of adenosine, functional adenosine receptor agonists which include 1-methyl-2-phenylethyladenosine, 5-ethyl carboxamide adenosine, cyclopentyl adenosine and 2-chloro adenosine; metabolic precursors or by-products of adenosine which include adenine and inosine; and phosphorylated derivatives of adenosine including adenosine monophosphate, adenosine diphosphate and adenosine triphosphate in conjunction with various invasive and noninvasive diagnostic techniques to detect the presence or assess the severity of vascular disease is a novel application (indication) for these compounds and forms the basis of this patent application.
Claims48
A method of detecting the presence and assessing the severity of myocardial dysfunction in a human comprising the steps of:
- (a) administering by an intravenous route to said human about 20 mcg/kg/minute to about 200 mcg/kg/minute of an adenosine receptor agonist sufficient to provide coronary artery dilation;
- and
- (b) performing a technique on said human to detect the presence and assess the severity of said myocardial dysfunction.
A method of detecting the presence and assessing the severity of myocardial dysfunction in a human comprising the steps of:
- (a) administering by an intracoronary route to said human about 2 mcg to about 20 mcg of an adenosine receptor agonist sufficient to provide coronary artery dilation;
- and
- (b) performing a technique on said human to detect the presence and assess the severity of said myocardial dysfunction.
A method of detecting the presence and assessing the severity of coronary artery disease in a human comprising the steps of:
- (a) administering by an intravenous route to said human about 20 mcg/kg/minute to about 200 mcg/kg/minute of an adenosine receptor agonist sufficient to provide coronary artery dilation
- (b) administering a radiopharmaceutical agent into said human;
- and
- (c) performing radiopharmaceutical myocardial perfusion imaging on said human in order to detect the presence and assess the severity of coronary artery disease.
A method of detecting the presence and assessing the severity of coronary artery disease in a human comprising the steps of:
- (a) administering by an intracoronary route to said human about 2 mcg to about 20 mcg of an adenosine receptor agonist sufficient to provide coronary artery dilation;
- (b) administering a radiopharmaceutical agent into said human;
- and
- (c) performing radiopharmaceutical myocardial perfusion imaging on said human in order to detect the presence and assess the severity of coronary artery disease.
A method of detecting the presence and assessing the severity of ventricular dysfunction caused by coronary artery disease, in a human, comprising the steps of:
- (a) administering by an intravenous route to said human about 20 mcg/kg/minute to about 200 mcg/kg/minute of an adenosine receptor agonist sufficient to provide coronary artery dilation;
- (b) performing a ventricular function imaging technique on said human;
- and
- (c) determining the presence and assessing the severity of ventricular dysfunction.
A method of detecting the presence and assessing the severity of ventricular dysfunction caused by coronary artery disease, in a human, comprising the steps of:
- (a) administering by an intravenous route to said human about 2 mcg to about 20 mcg of an adenosine receptor agonist sufficient to provide coronary artery dilation;
- (b) performing a ventricular function imaging technique on said human;
- and
- (c) determining the presence and assessing the severity of ventricular dysfunction.
A method of determining the difference between the coronary blood flow through disease free coronary vessels and stenotic coronary vessels in a human comprising the steps of:
- (a) administering by an intravenous route to said human about 20 mcg/kg/minute to about 200 mcg/kg/minute of an adenosine receptor agonist sufficient to provide coronary artery dilation;
- (b) performing a method for measuring coronary blood flow velocity on said human in order to assess the vasodilatory capacity of disease free coronary vessels as opposed to stenotic coronary vessels.
A method of determining the difference between the coronary blood flow through disease free coronary vessels and stenotic coronary vessels in a human comprising the steps of:
- (a) administering by an intracoronary route to said human about 2 mcg to about 20 mcg of an adenosine receptor agonist sufficient to provide coronary artery dilation;
- (b) performing a method for measuring coronary blood flow velocity on said human in order to assess the vasodilatory capacity (reserve capacity) of disease free coronary vessels as opposed to stenotic coronary vessels.
A method of detecting the presence and assessing the severity of coronary artery disease in a human comprising the steps of:
- (a) administering to said human by intravenous infusion about 20 mcg/kg/minute to about 200 mcg/kg/minute of adenosine in order to provide coronary artery dilation;
- (b) administering thallium-201 to said human;
- and
- (c) performing the scintigraphy on said human in order to detect the presence and assess the severity of coronary artery disease.
A method of detecting the presence and assessing the severity of ventricular dysfunction in a human comprising the steps of:
- (a) administering to said human by intravenous infusion about 20 mcg/kg/minute to about 200 mcg/kg/minute of adenosine in order to provide coronary artery dilation;
- (b) performing an echocardiography on said human;
- and
- (c) determining the presence and assessing the severity of ventricular dysfunction.
A method of determining the difference between coronary blood flow through disease free coronary vessels and stenotic coronary vessels in a human comprising the steps of:
- (a) administering to said human by intracoronary bolus injection about 2 mcg to about 20 mcg of adenosine, in order to provide coronary artery dilation;
- (b) measuring the difference between coronary blood flow through disease-free coronary vessels and stenotic coronary vessels in said human using a doppler flow catheter in order to assess the vasodilatory capacity (reserve capacity) of disease-free coronary vessels as opposed to stenotic coronary vessels.
A method of detecting the presence and assessing the severity of coronary artery disease in a human comprising the steps of:
- (a) administering to said human by intracoronary bolus injection about 2 mcg to about 20 mcg of adenosine in order to provide coronary artery dilation;
- (b) administering thallium-201 to said human;
- and
- (c) performing scintigraphy on said human in order to detect the presence and assess the severity of coronary artery disease.
A method of detecting the presence and assessing the severity of ventricular dysfunction in a human comprising the steps of:
- (a) administering to said human by intracoronary bolus injection about 2 mcg to about 20 mcg of adenosine in order to provide coronary artery dilation;
- (b) performing an echocardiography on said human;
- and
- (c) determining the presence and assessing the severity of ventricular dysfunction.
A method of determining the difference between coronary blood flow through disease free coronary vessels and stenotic coronary vessels in a human comprising the steps of:
- (a) administering to said human by intravenous infusion about 20 mcg/kg/minute to about 200 mcg/kg/minute of adenosine, in order to provide coronary arter dilation;
- (b) measuring the difference between coronary blood flow through disease-free coronary vessels and stenotic coronary vessels in said human using a Doppler flow catheter in order to assess the vasodilatory capacity (reserve capacity) of disease-free coronary vessels as opposed to stenotic coronary vessels.
Dependencies are inferred from the claim text.